EVLO Stock Overview
A clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Evelo Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.06 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | -40.00% |
| 3 Month Change | -40.00% |
| 1 Year Change | -99.26% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?
Aug 18
Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03
Aug 11Marella Thorell is the new finance chief of Evelo Biosciences
Jul 18Evelo Biosciences: Hope After Dilution?
Jun 06Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?
Mar 21Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?
Sep 25What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?
Mar 11Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares
Dec 15
Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?
Dec 11Shareholder Returns
| EVLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.7% | 5.3% |
| 1Y | -99.3% | -14.5% | 11.9% |
Return vs Industry: EVLO underperformed the US Biotechs industry which returned -14.5% over the past year.
Return vs Market: EVLO underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| EVLO volatility | |
|---|---|
| EVLO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: EVLO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine EVLO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | n/a | n/a |
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.
Evelo Biosciences, Inc. Fundamentals Summary
| EVLO fundamental statistics | |
|---|---|
| Market cap | US$5.69k |
| Earnings (TTM) | -US$82.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs EVLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVLO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$82.35m |
| Earnings | -US$82.35m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EVLO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 06:27 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evelo Biosciences, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |